- Home
- SATL vs MCRB Comparison
SATL vs MCRB Comparison
Compare SATL & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- MCRB
- Stock Information
- Founded
- SATL 2010
- MCRB 2010
- Country
- SATL United States
- MCRB United States
- Employees
- SATL N/A
- MCRB N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- SATL Technology
- MCRB Health Care
- Exchange
- SATL Nasdaq
- MCRB Nasdaq
- Market Cap
- SATL 178.8M
- MCRB 144.8M
- IPO Year
- SATL N/A
- MCRB 2015
- Fundamental
- Price
- SATL $1.47
- MCRB $16.89
- Analyst Decision
- SATL
- MCRB Hold
- Analyst Count
- SATL 0
- MCRB 3
- Target Price
- SATL N/A
- MCRB $14.33
- AVG Volume (30 Days)
- SATL 3.3M
- MCRB 320.0K
- Earning Date
- SATL 11-10-2025
- MCRB 11-05-2025
- Dividend Yield
- SATL N/A
- MCRB N/A
- EPS Growth
- SATL N/A
- MCRB N/A
- EPS
- SATL N/A
- MCRB 0.62
- Revenue
- SATL $14,684,000.00
- MCRB $351,000.00
- Revenue This Year
- SATL N/A
- MCRB N/A
- Revenue Next Year
- SATL N/A
- MCRB N/A
- P/E Ratio
- SATL N/A
- MCRB $28.60
- Revenue Growth
- SATL N/A
- MCRB N/A
- 52 Week Low
- SATL $1.20
- MCRB $6.53
- 52 Week High
- SATL $5.49
- MCRB $29.98
- Technical
- Relative Strength Index (RSI)
- SATL 34.22
- MCRB 47.23
- Support Level
- SATL $1.26
- MCRB $12.48
- Resistance Level
- SATL $1.41
- MCRB $29.98
- Average True Range (ATR)
- SATL 0.12
- MCRB 3.31
- MACD
- SATL 0.04
- MCRB 0.40
- Stochastic Oscillator
- SATL 37.84
- MCRB 26.22
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.